CD5+MYC+ predicts worse prognosis in diffuse large B-cell lymphoma
2019
Abstract The dual expression of CD5 and MYC protein (DECM) on B-lymphocytes may arise at a specific stage of de novo diffuse large B-cell lymphoma (DLBCL). This study retrospectively reviewed 210 patients with de novo DLBCL at the Affiliated Hospital of Jiangnan University between 2006 and 2017. DECM was significantly correlated with a worse prognosis than that in either the CD5+ or MYC+ or CD5−MYC− patients. Furthermore, patients with DECM showed a similar outcome to MYC+BCL2+ lymphoma patients who have extremely poor survival rates. Multivariate analysis demonstrated that DECM was a significant independent predictor for overall survival (P
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
25
References
0
Citations
NaN
KQI